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Abstract: Exchanges between the blood compartment and the surrounding tissues require a tight 
regulation by the endothelial barrier. Recent reports inferred that VE-cadherin, an endothelial 
specific cell-cell adhesion molecule, plays a pivotal role in the formation, maturation and remodeling 
of the vascular wall. Indeed, a growing number of permeability inducing factors (PIFs) elicits 
signaling mechanisms culminating at VE-cadherin destabilization and global alteration of the 
junctional architecture. Conversely, anti-PIFs militate against VE-cadherin disruption and enhance 
cell cohesion. These findings shed a new light on how endothelial cell-cell junctions impact the 
vascular network, and change our perception about normal and aberrant angiogenesis. 
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Under physiologic conditions and depending 
on the vascular sites, the exchange of fluids, 
cells, and nutrients between the blood 
compartment and the surrounding tissues can 
be increased or decreased. Endothelial cells 
that line the vascular wall act thus as 
gatekeepers to control the infiltration of blood 
proteins and circulating cells to the underlying 
tissues. This vascular permeability contributes 
to normal angiogenesis, blood pressure 
control, as well as immune responses [1]. 
Moreover, many pathological conditions and 
human diseases exhibit an abnormal increase 
in vascular permeability, such as tumor-
induced angiogenesis, inflammation, macular 
degeneration, allergy, and brain stroke. It has 
been described that endothelial permeability 
can be mediated by transcellular and 
paracellular pathways, where plasma 
molecules and cells can pass through 
(transcellular) or between (paracellular) 
endothelial cells. Transcellular passage 
requires either cell fenestration or a complex 
system of transport vesicles, called vesiculo-
vacuolar organelles. The paracellular 
pathway, by contrast, is mediated by the 
coordinated opening and closure of 
endothelial cell-cell junctions. This latter 
function must therefore be tightly regulated to 
maintain the endothelial integrity. 
 
1. Endothelial cell-cell junctions required 
functional VE-cadherin adhesion 
 The adhesive contacts between cells 
underlie many morphogenetic processes 
during embryonic development as well as 
growth control, turnover, and regeneration of 
adult tissues. The formation, maintenance, 
and remodeling of the intercellular contacts 
implies a functional interaction between two 
main adhesive structures: tight junctions and 
adherens junctions (Figure 1). Cadherins, the 
main constituent of the adherens junctions, 
belong to a conserved family of adhesion 
molecules that provide a molecular bond 
between cells and link the plasma membrane 
with the intracellular actin cytoskeleton 
through catenin family proteins [2]. Tight 
junctions form a dense ultra-structure 
organization, observable by electron 
microscopy, which involves numerous 
adhesive molecules, including the claudin 
family of tetraspan transmembrane proteins, 
occludins, and junctional adhesion molecules 
(JAMs), as well as the intracellular adapters, 
namely zona occludens proteins, ZO-1 and 
ZO-2 [3]. Whereas in epithelial cells, tight 
junctions are often located apically with 
respect to adherens junctions, in endothelial 
cells, both junctions are intermingled 
throughout cell-cell contact areas [4]. 
 The barrier properties require the 
adhesive activities of VE-cadherin and 
claudin-5, which are key components of the 
adherens and tight endothelial junctions, 
respectively (Figure 1). Indeed, 
macromolecule passage is enhanced through 
claudin-5 and VE-cadherin-deficient 
endothelial monolayers in vitro [5,6]. In 
endothelial cells, VE-cadherin is highly 
expressed and located at adherens junctions. 
Its expression profile appears early and 
restricted into the endothelial cell lineage, 
such that its promoter has been used to 
trigger transgene expression specifically in the 
endothelial compartment [7]. In addition, N-
cadherin is also found at high levels in 
endothelial cells but exhibits a weak clustering 
within endothelial cell-cell junctions and 
occupied preferentially apical locations. 
Indeed, N-cadherin was suggested to play a 
role in vascular stabilization through 
heterotypic adhesion between endothelial 
cells and pericytes [8]. Interestingly, while 
claudin-5 knockout mice develop normally but 
have a defective blood brain barrier function 
and die shortly after birth [9], VE-cadherin 
knockout mice are embryonic lethal and 
exhibit multiple severe defects during 
developmental angiogenesis [10]. In 
agreement, VE-cadherin is required to prevent 
the disassembly of the blood vessel walls [11], 
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and to coordinate the passage of 
macromolecules through the endothelium in 
vitro [5,12]. Finally, VE-cadherin has been 
recently shown to directly enhance the 
expression level of claudin-5 by tethering 
repressive transcription factors away from the 
claudin-5 promoter [6]. Conversely, the 
absence of functional VE-cadherin is 
associated with loss of claudin-5 expression, 
suggesting that VE-cadherin adhesion might 
act upstream in the formation and 
maintenance of the endothelial barrier 
integrity. In conclusion, VE-cadherin function 
in endothelial cells is intimately linked to 
vascular integrity and endothelial barrier 
plasticity. 
 
2. Molecular basis for VE-cadherin 
adhesive function 
 VE-cadherin belongs to the cadherin 
super-family of cell-cell adhesion molecules, 
which constituted more than two hundred 
genes encoding cadherins in the human 
genome [13]. Among them, classical 
cadherins are Ca2+-dependent, homophilic, 
cell to cell adhesion molecules expressed in 
nearly all cells within solid tissues. These 
molecules also participate in cell-cell 
recognition, a property that confers the ability 
of cells to aggregate with and ultimately sort 
their most physiologically relevant cell 
partners. It is generally admitted that 
cadherins form a core adhesion complex that 
consists of a cadherin dimer, binding through 
its extracellular region to another dimer of 
cadherins expressed in adjacent cells, and an 
intracellular region, anchored to the plasma 
membrane and linked to the cytoskeleton [14]. 
 Similarly to other typical cadherins, the 
VE-cadherin extracellular domain consists of 
five cadherin-type repeats, called EC 
(extracellular cadherin) domains that are 
bound together by calcium ions in a rod-like 
structure [14]. Interestingly, VE-cadherin lacks 
the HAV tripeptide, localized in the EC1 
repeat, which has been discussed to 
participate in cell-cell adhesion recognition in 
the case of E- and N-cadherin-mediated 
contacts. Based on information obtained by 
the use of purified recombinant proteins 
containing either fragments or total ECs, it is 
observed that multiple EC interactions 
promote the formation of a completely inter-
digitated hexameric configuration. Of note, 
this hexameric structure might be specific for 
VE-cadherin, and has been proposed to favor 
its membrane stability [15]. Once engaged in 
homophilic interactions, the extracellular 
domains develop additional forces, 
strengthening the adhesive contacts while 
retaining the ability to associate and to 
dissociate rapidly in response to dynamic 
changes in the cellular environment. 
Classical cadherins are single-pass 
transmembrane proteins that interact with a 
number of different cytoplasmic partners to 
carry out their functions, which include cell-
cell adhesion, cytoskeletal anchoring, 
immediate intracellular signaling and 
transcriptional control. The cadherin-
associated proteins, catenins, are universally 
present in classical cadherin complexes [13]. 
In particular, β-catenin interacts with the distal 
part of the cadherin cytoplasmic domain and 
p120 catenin with a more proximal region. α-
catenin does not bind directly to cadherin, but 
instead associates with β-catenin, and 
provides a physical links to the actin 
cytoskeleton, either by directly binding to actin 
filaments or indirectly through other actin-
binding proteins such as vinculin, α-actinin, 
and formins thus regulating actin 
polymerization, cross-linking and dynamics at 
the cell-cell contact zones [16]. In addition, β-
catenin could be substituted to γ-catenin, 
which has been suggested to associate 
preferentially with vimentin network, and 
therefore may provide a link between VE-
cadherin-mediated junctions and the 
intermediate filament cytoskeleton [4]. On the 
other hand, p120 catenin seems to influence 
cadherin function by a variety of mechanisms, 
which includes plasma membrane stability, 
recycling and cell surface targeting [17]. 
Page 4 
 
Therefore, disrupting the endothelial cell-
cell junctions implies to disconnect VE-
cadherin intracellular domain from essential 
cohesive mediators, as well as weakening its 
extracellular homophilic interactions. 
 
3. How do permeability inducing factors 
(PIFs) disrupt VE-cadherin bonds? 
 There is a growing number of angiogenic 
and inflammatory agents that have been 
shown to modulate vascular integrity in vivo 
and barrier properties of endothelial 
monolayers in vitro. They can be collectively 
named as permeability inducing factors 
(PIFs), independently of their mode of actions 
(Table 1). Several studies have primarily 
focused on their effects on the endothelial 
cell-cell junction organization and have 
permitted to unveil key molecular and cellular 
mechanisms involved in the endothelial 
barrier remodeling. Four interconnected 
pathways can be elicited by PIFs to increase 
endothelial permeability, leading ultimately to 
the loss of VE-cadherin function, through: 1) 
phosphorylation-driven VE-cadherin/catenin 
complex destabilization, 2) cell surface 
expression, 3) crosstalk to tight junctions, and 
4) tension and mechanical forces (Figure 2). 
 First, phosphorylation has been described 
early as a prominent mechanism by which 
cadherins and catenin interaction can be 
modulated, either positively or negatively, and 
therefore might decipher for overall adhesion 
forces. To this regard, VE-cadherin bears nine 
putative phospho-tyrosine sites, among which 
Y658, Y685 and Y731 have been individually 
found to be implicated in the barrier integrity 
[18,19]. In addition, S665 has been identified 
as a pivotal regulator of VE-cadherin 
exposure at the plasma membrane [5]. Of 
note, the vascular endothelial growth factor 
(VEGF) was demonstrated to trigger VE-
cadherin phosphorylation and remodeling in 
endothelial cells [20]. Similarly, most of the 
PIFs tested so far are associated with an 
increase in VE-cadherin tyrosine 
phosphorylation and diminution of VE-
cadherin/catenin binding. While several 
kinases have been reported to contribute to 
VE-cadherin phosphorylation status, the exact 
molecular mechanisms by which such 
tyrosine phosphorylation promotes vascular 
leakage are still elusive [4]. However, the non-
receptor tyrosine kinases of the Src family 
appear involved in this biological effect. 
Indeed, Src-deficient mice show decreased 
vascular leakage and VE-cadherin tyrosine 
phosphorylation notably in response to VEGF 
and histamine [21]. More striking, blocking Src 
activity can efficiently restore the barrier 
integrity even in pathological context such as 
brain stroke, tumor cell extrasavation and 
retinal hyper-permeability [22-24]. 
 Second, reduction of VE-cadherin stability 
at the plasma membrane might contribute to 
compromise endothelial barrier integrity. 
Interestingly, internalization of VE-cadherin 
has been observed in response to monocyte 
extrasavation, inhibition of FGF signaling and 
activation of VEGF-R2 by VEGF [5,25,26]. 
Indeed, VEGF triggers the hierarchical 
activation of the Src tyrosine kinase, Vav2, a 
guanine-nucleotide exchange factor for the 
small Rho GTPases, Rac and its downstream 
effector PAK, the p21-activated kinase [5]. 
This signaling axis culminates at the PAK-
dependent phosphorylation of VE-cadherin, 
on a highly conserved serine residue, which 
directs VE-cadherin to endocytosis [5]. Of 
note, active forms of PAK have been reported 
to be localized at cell-cell junctions upon PIF 
exposure [27]. Alternatively, decreasing the 
association between VE-cadherin and p120 
catenin leads to clathrin-dependent VE-
cadherin endocytosis [28]. Indeed, blocking 
FGF signaling in endothelial cells triggers the 
dissociation between VE-cadherin and p120, 
leading to disassembly of adherens junctions 
and impairment of vascular integrity [26]. 
Finally, VE-cadherin cell surface expression is 
frequently altered in hyper-permeability 
conditions such as inflammation, diabetes, 
and virus exposure [29-31]. Ultimately, PIF 
dose, kinetics and mode of action might 
control the fate of internalized VE-cadherin 
and drive it to temporary storage 
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compartment, recycling pathway, or 
degradation. 
 Third, increase in endothelial monolayer 
permeability is generally accompanied by the 
reorganization of junctional proteins and a 
subsequent increase in paracellular 
permeability. Not only VE-cadherin has been 
found to be relocated and phosphorylated 
upon diverse PIF stimulation, but similar 
observations have also been made for tight 
junction components [32]. Interestingly, the 
diminution of VE-cadherin plasma membrane 
exposure corroborates with compromised 
organization of the endothelial tight junctions 
[5,26]. As reported in epithelial cells, these 
observations suggest a functional crosstalk 
between VE-cadherin and tight junctions [3]. 
This hypothesis has been further 
demonstrated in endothelial cells lacking VE-
cadherin expression or its adhesive activity. 
Indeed, in such cells, claudin-5 mRNA is 
down regulated, while rescuing VE-cadherin 
function triggers claudin-5 transcription [6]. 
Hence, VE-cadherin can directly control 
claudin-5 expression, and therefore the 
organization and maturation of endothelial 
tight junctions. At the molecular level, VE-
cadherin adhesion prevents from β-catenin 
and FoxO binding to claudin-5 promoter 
where they could repress its transcription. 
These data offer a fine molecular mechanism 
by which VE-cadherin encrypts overall 
endothelial cell-cell junction architecture. On 
the other hand, the loss of junctional adhesion 
molecule, JAM-C, expression results in 
stabilization of VE-cadherin-mediated 
adhesion, while its expression corroborates 
with an increase in the endothelial 
permeability [33]. Despite these recent 
advances, little is still known on the crosstalk 
between adherens and tight junction in 
endothelial cells. 
 Finally, endothelial permeability largely 
depends on actomyosin-based cell 
contractility, as intracellular stress fibers exert 
centripetal tension on intercellular junctions 
[34]. Inhibition of acto-myosin contractility by 
pharmacological agents, as well as 
examination of myosin light chain (MLC) 
phosphorylation status had placed mechanical 
forces in the pathway by which PIFs, such as 
thrombin and histamine exert their effects 
[35]. MLC phosphorylation mainly relies on 
the activation of the small GTPase, RhoA, 
which in turn controls two serine/threonine 
kinases, namely ROCK and PRK [35-37]. 
Interestingly, elevation of intracellular calcium 
signaling has been shown upstream RhoA 
activation in such biochemical routes [37,38]. 
In addition, blocking PAK-dependent acto-
myosin contractility prevents from endothelial 
permeability increased by several PIFs, such 
as VEGF, histamine, TNFα (tumor necrosis 
factor), LPS (lipopolysaccharide from the 
bacterial wall), as well as atherosclerotic risk 
factors [27,39]. 
 In conclusion, it is most likely that 
coordinated disruption of VE-cadherin 
intracellular interactions by phosphorylation, 
internalization, and mechanical forces 
contributes to the destabilization and the 
disengagement of VE-cadherin adhesion, 
culminating at the subsequent opening of 
endothelial cell-cell junctions. 
4. Looking for anti-permeability inducing 
factor (anti-PIFs) mechanisms 
 Few angiogenic mediators have been 
identified based on their anti-permeability 
action, although blocking vascular leakage 
may have direct implications in modulating 
angiogenesis and inflammation, as well as 
therapeutic potentials in the treatment of 
many human diseases characterized by loss 
of vascular integrity. In this paragraph, I will 
discuss the proposed mechanisms on the 
endothelial barrier function of anti-permeability 
inducing factors (anti-PIFs), among them: 
angiopoietin-1 and its cognate receptor Tie2, 
FGF (for fibroblast growth factor), Robo-4, 
cAMP-elevating G protein-coupled receptor 
(GPCR) agonists and S1P (sphingosine-1-
phosphate) (Table 2 and Figure 2). 
 First, angiopoietin-1, such as VEGF, is a 
potent pro-angiogenic factor, but whereas 
VEGF causes vascular permeability, 
angiopoietin-1 stabilizes blood vessels and 
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protects from VEGF-induced vascular 
permeability. Indeed, angiopoietin-1 
administration or overexpression in the dermal 
compartment can protect from the potentially 
lethal actions of VEGF as a consequence of 
uncontrolled plasma leakage [40]. In this 
regard, angiopoietin-1 can potently block 
VEGF-induced endothelial permeability in 
vitro [41], suggesting that their opposing 
effects on vascular leakage may be exerted 
through direct stimulation of endothelial cells. 
In addition, angiopoietin-1 might exert a 
general anti-vascular permeability effect, 
protecting blood vessels from the plasma 
leakage caused by thrombin and bacterial wall 
components, such as LPS [41,42]. Thus, the 
angiopoietin-1/Tie2 endothelial signaling axis 
might play a key anti-inflammatory role in 
various diseases such as asthma, rheumatoid 
conditions and septic shock. Several signaling 
mediators, including calcium signaling or 
GTPase Activating Proteins (GAPs) for RhoA, 
have been proposed to oppose the 
endothelial barrier disruption [42,43], but the 
exact molecular mechanisms were still 
unknown. Based on our recent findings, we 
investigated whether angiopoietin-1 might 
impede on the phospho-serine-dependent 
internalization of VE-cadherin [5]. Indeed, we 
have obtained evidence that angiopoietin-1 
elicits a signaling pathway through Tie2, 
which can compete for Src activation by 
VEGF-R2, therefore halting the VEGF 
signaling to VE-cadherin internalization [44]. 
Similar Src inhibition has been demonstrated 
as well to oppose VEGF-induced vascular 
permeability in response to Robo-4, a ligand 
for the endothelial Slit-2 receptor [45]. 
Interestingly, Tie2 is localized at cell-cell 
junctions in an intact endothelial monolayer, 
where it contributes to stabilize VE-cadherin 
adhesion, in association with the vascular 
endothelial phospho-tyrosine phosphatase 
(VE-PTP) [46,47]. Both Tie2 localization and 
downstream signaling are modified in the 
absence of endothelial cell-cell contacts, 
suggesting a regulatory feedback between 
VE-cadherin adhesion and Tie2 function. This 
“super” clustering of adhesion and signaling 
receptors at the contacting zones might then 
preserve controlled paracellular permeability. 
 In addition to angiopoietin-1 action, 
membrane stability of VE-cadherin is also 
involved in the protective mechanism exerted 
by FGF signaling during vascular maturation 
[26]. Indeed, inhibition of FGF signaling 
reduces the interaction between p120 and 
VE-cadherin, while VE-cadherin 
internalization is enhanced [26]. Interestingly, 
such interaction has been shown to be critical 
to prevent from VE-cadherin endocytosis [28]. 
Finally, cAMP-Epac-Rap1 signaling promotes 
decreased paracellular permeability by 
enhancing VE-cadherin-mediated adhesion, in 
response to cAMP-elevating G protein-
coupled receptor (GPCR) agonists, such as 
prostaglandin E2 and atrial natriuretic peptide 
(ANP) [12,48,49]. Cytoskeletal rearrangement 
and barrier enhancement through Rac 
activation have been on the other hand 
proposed to militate for vascular integrity by 
S1P signaling [50], while reinforcement of 
endothelial cell/pericyte interaction through N-
cadherin adhesion cannot be excluded in its 
anti-PIF effects [8]. Discovery of novel anti-
PIFs has accelerated in the past years and 
research in this field had direct implications in 
the search for therapeutic drugs designed to 
target aberrant vascular leakiness, 
inflammation, and edema. 
 Thus, recent reports suggest that 
protection of VE-cadherin adhesion largely 
contributed to anti-PIF molecular 
mechanisms, such as through angiopoietin-1, 
FGF, and intracellular Rap signaling, while 
actin rearrangement and cell adhesion 
collectively can also control the endothelial 
barrier properties. 
 Despite our progresses in the 
understanding of the molecular mechanisms 
regulating VE-cadherin function in the 
endothelial barrier, the dynamics of VE-
cadherin trafficking, including endocytosis and 
recycling are not elucidated yet. Ultimately, 
the biochemical route by which VEGF, 
angiogenic factors and oncogenes modulate 
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VE-cadherin, cell-cell junctions and vascular 
integrity may help identify new therapeutic 
targets for the treatment of many human 
diseases that exhibit aberrant vascular 
leakage. Of note, past efforts in angiogenesis 
field had led to the approval of anti-VEGF 
drugs in colon cancer treatment and ocular 
diseases. However, this drug is not suitable 
for all patients, can affect normal vasculature 
and exhibit tumor recurrence upon therapy 
withdraw. Hence, it will be crucial in the future 
to ascertain the molecular basis for the 
development of novel therapeutic targets 
designed to promote normalization of the 
vascular wall and its micro-environment. 
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Table 1. Permeability inducing factors (PIFs) and their proposed modes of action 
 
 
PIFs Effects on VE-cadherin Proposed Signaling pathways 
 
 Phosphorylation Src 
VEGF Internalization Rac/PAK 
 Catenin dissociation Ca++/PKC 
 Ca++/PKC 
 Catenin dissociation Rho 
Thrombin Phosphorylation Rac/PAK 
 MAPK 
 Phosphorylation Ca++/PKC 
Histamine Catenin dissociation Rho 
 Internalization Rac/PAK 
 Ca++/PKC 
TNFα Phosphorylation Rho 
 Rac/PAK 
 Rho 
LPS Phosphorylation Indirect 
 Src 
 Phosphorylation Rac/PAK 
ROS Catenin dissociation Src 
 Ca++/PKC 
 
LPS: LipoPolySaccharide; PAK; p21-activated kinase; PKC: protein kinase C; ROS: reactive oxygen 
species; TNF: Tumor Necrosis Factor; VEGF: Vascular Endothelial Growth Factor. Some PIFs are not 
listed here, such as bradykinine, as their effects have been suggested to be specific of the endothelial 
cell models used.  
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Table 2. Anti-Permeability inducing factors (anti-PIFs) and their effects on the endothelial barrier 
 
 
Anti-PIFs Signaling system Effects on the endothelial barrier 
 
 Tie-2 VE-cadherin membrane stabilization 
Angiopoietin-1 Rho-GAP Src - Ca++ pathway inhibition 
 mDia Acto-myosin contractility 
 VE-cadherin membrane stabilization 
Robo-4 Slit-2 Src inhibition 
S1P S1P-R1 Rac/PAK 
cAMP-GPCR Rap VE-cadherin membrane stabilization 
FGF FGF-R1 VE-cadherin membrane stabilization 
 
cAMP-GPCR: cyclic adenosine monophosphate elevating G-protein coupled receptor; FGF: fibroblast 
growth factor; GAP: GTPase Activating Protein; mDia: mammalian diaphanous; PAK: p21-activated 
kinase; R: receptor; S1P: sphingosine 1 Phosphate. 
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Figure 1. Endothelial cell-cell junctions. 
Adherens and tight junctions sealed the endothelial cell contacts through specific cell-cell adhesion molecules: 
VE-cadherin, JAM (junctional adhesion molecules), claudin-5, occludin. Through intracellular mediators: p120 
catenin, α, β and γ catenins (cat), zona occludens (ZO) proteins, they are linked to the intracellular 
cytoskeleton of actin and vimentin. VE-cadherin has also been characterized for its interaction with signaling 
component such as: phospho-inositide 3 Kinase (PI3K), vascular endothelial growth factor receptor type 2 
(VEGF-R2), vascular endothelial cell-specific phospho-tyrosine phosphatase (VE-PTP) and the angiopoietin-1 
receptor, Tie2. 
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Figure 2. VE-cadherin adhesion controls the endothelial barrier properties. 
Four interconnected pathways can be elicited by permeability inducing factors (PIFs) to increase endothelial 
permeability, leading ultimately to the loss of VE-cadherin function, through: 1) mechanical and tension forces, 
2) phosphorylation-driven VE-cadherin/catenin complex destabilization, 2) cell surface expression, 3) 
crosstalk to tight junctions. Essential mediators such as the kinases: Pyk2, PAK and Src and the biochemical 
routes involving the RhoA and Calcium signaling axis. At the opposite, anti-PIFs elicit signaling mechanisms 
hampering on Src and Rho activation, calcium signaling, VE-cadherin phosphorylation, acto-myosin 
contractility and actin polymerization, or enhancing VE-cadherin cell surface exposure through Rap signaling 
axis. Ultimately, anti-PIFs can reinforce VE-cadherin adhesion and therefore the integrity of the endothelial 
barrier. 
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